Clinical Trials Logo
  1. Home
  2. Liver Metastases
  3. NCT01706432

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Liver Metastases Clinical Trial

Official title:
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)

Clinical Trial Summary

This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Breast Carcinoma In Situ
  • Breast Neoplasms
  • Breast Neoplasms, Male
  • Carcinoma
  • Carcinoma in Situ
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Central Nervous System Metastases
  • Invasive Ductal Breast Carcinoma
  • Invasive Ductal Breast Carcinoma With Predominant Intraductal Component
  • Invasive Lobular Breast Carcinoma
  • Invasive Lobular Breast Carcinoma With Predominant in Situ Component
  • Liver Metastases
  • Lobular Breast Carcinoma in Situ
  • Lung Metastases
  • Male Breast Cancer
  • Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate
  • Mucinous Ductal Breast Carcinoma
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Papillary Ductal Breast Carcinoma
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Tubular Ductal Breast Carcinoma
  • Tumors Metastatic to Brain
Clinical Trial Details
NCT number NCT01706432
Study type Observational
Source University of Chicago
Contact
Status Active, not recruiting
Phase
Start date June 15, 2009
Completion date September 1, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Terminated NCT02465112 - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor Phase 3
Completed NCT02352259 - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Phase 2
Active, not recruiting NCT01763450 - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Phase 2
Withdrawn NCT01631539 - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC N/A
Recruiting NCT01250158 - Liver-PILP First-in-Man N/A
Terminated NCT01233544 - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases Phase 3
Completed NCT01347333 - Stereotactic Body Radiotherapy for Liver Tumors N/A
Completed NCT00587756 - Alternative to Two-Stage Hepatectomy N/A
Completed NCT01683357 - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Not yet recruiting NCT05354674 - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting NCT04509635 - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Phase 3